CF PharmTech, Inc. repurchased 14,000 H-shares on 12 June 2026 through on-market transactions in Hong Kong. The shares were bought at prices ranging from HKD 17.83 to HKD 18.15, with a volume-weighted average cost of HKD 17.98, bringing total consideration to approximately HKD 0.25 million.

Following the transaction, issued shares (excluding treasury shares) decreased to 300.84 million, while treasury shares rose to 1.38 million. The repurchase reduced the company’s outstanding share capital by 0.0047%.

The buyback forms part of a mandate approved on 16 December 2025, which authorises the company to repurchase up to 30.22 million shares. Cumulative repurchases under this mandate now stand at 1.38 million shares, representing 0.46% of the issued share count as at the mandate date.

In line with Hong Kong listing regulations, CF PharmTech is subject to a moratorium on issuing new shares or disposing of treasury shares until 12 July 2026.